Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Lindbrook Capital LLC

Lindbrook Capital LLC raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 16.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,786 shares of the medical equipment provider’s stock after acquiring an additional 255 shares during the quarter. Lindbrook Capital LLC’s holdings in Hologic were worth $128,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. acquired a new position in Hologic during the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC purchased a new stake in shares of Hologic during the third quarter valued at approximately $29,000. NBC Securities Inc. purchased a new stake in shares of Hologic during the third quarter valued at approximately $33,000. Deseret Mutual Benefit Administrators raised its stake in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares during the period. Finally, Massmutual Trust Co. FSB ADV raised its stake in shares of Hologic by 69.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HOLX. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Wednesday, April 10th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Finally, Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $87.00.

Insider Buying and Selling at Hologic

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock worth $2,473,443 over the last 90 days. Insiders own 1.75% of the company’s stock.

Hologic Stock Up 1.3 %

HOLX stock opened at $77.19 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88. The firm has a fifty day moving average price of $75.87 and a two-hundred day moving average price of $72.69. The firm has a market cap of $18.12 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 2.58 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. Research analysts predict that Hologic, Inc. will post 4.01 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.